On August 18, the FDA approved high-dose, 8 mg Aflibercept (EYLEA HD) for the treatment of wet AMD, diabetic macular edema (DME) and diabetic retinopathy (DR).
In this video, Paolo Lanzetta, MD, and Jean-François Korobelnik, MD, PhD, speak about the two pivotal PHOTON and PULSAR trials, the advantages of longer durability, and how they expect that this new option will be used in real-world clinical practice.